<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256217</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 03-16 [HS# 2004-3681]</org_study_id>
    <secondary_id>2004-3681</secondary_id>
    <secondary_id>NCI-2010-00361</secondary_id>
    <nct_id>NCT00256217</nct_id>
  </id_info>
  <brief_title>Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women</brief_title>
  <official_title>Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rita Sanghvi, Mehta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is one of the most common cancers seriously afflicting women in the United&#xD;
      States. Of the one million incident cases that are reported annually there are approximately&#xD;
      193,000 new cases of breast cancer (Greenlee, 2001). Although significant advances have been&#xD;
      made both in early detection and treatment of breast cancer, the impact of these on reduction&#xD;
      in mortality has been modest (Peta, 2000). Furthermore, despite data implicating diet and&#xD;
      other environmental risk factors, no lifestyle changes have yet been shown to significantly&#xD;
      reduce the risk of breast cancer. Therefore, chemoprevention of breast cancer is a worthwhile&#xD;
      approach to reduce the incidence of breast cancer.&#xD;
&#xD;
      There is every reason to believe that a detailed understanding of the initiation, promotion&#xD;
      and growth of breast cancer will ultimately provide a rational strategy upon which to base&#xD;
      prevention strategies. While the pathways of breast cancer development are not yet fully&#xD;
      understood, a role for estrogens in breast cancer etiology has been well established.&#xD;
&#xD;
      While many pathways are involved in breast cancer etiology, including loss of tumor&#xD;
      suppressor function by p53 or BRCA1 and gain of HER2 oncogene expression, their exact role in&#xD;
      an individual patient's cancer development may vary.&#xD;
&#xD;
      Therefore, it may be advantageous to focus on a chemoprevention strategy that may have a more&#xD;
      uniform impact on breast cancer development, such as estrogen exposure. Estrogen and its&#xD;
      metabolites, both in the circulation and locally synthesized in the breast, are important in&#xD;
      the pathogenesis of breast cancer. High levels of circulating estrogen in postmenopausal&#xD;
      women have been associated with an increased risk of breast cancer (Clemons, 2001).&#xD;
      Furthermore, local estrogen synthesis, i.e. aromatase activity, in the breast may also be&#xD;
      important in the development of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: We hypothesize that a proliferative marker Ki-67 is reduced in patients with&#xD;
      preinvasive Ductal Carcinoma In Situ (DCIS) and very early breast cancer treated with&#xD;
      anastrozole. To establish reduction in Ki-67 as a primary surrogate endpoint to breast cancer&#xD;
      risk reduction in patients treated with anastrozole we will measure Ki-67 before and after&#xD;
      treatment with anastrozole. Consistent with this, it has been demonstrated by Geisler et al&#xD;
      that patients with advanced breast cancer show a decrease in Ki-67 on lumpectomy/mastectomy&#xD;
      samples when anastrozole is administered for few weeks prior to definitive surgery. In&#xD;
      addition, there is a trend for a more profound suppression in those achieving an objective&#xD;
      response. Ki-67 will be measured by routine immunohistochemistry.&#xD;
&#xD;
      Specific Aim 2: We hypothesize that histopathological tumor response will be demonstrated in&#xD;
      30-40 percent of patients with preinvasive (DCIS) and early invasive (less than 2 cm) breast&#xD;
      cancer treated with anastrozole. The percent ability to reverse early breast cancer lesions&#xD;
      in patients treated with anastrozole will be qualified as a secondary surrogate endpoint to&#xD;
      breast cancer risk reduction. Consistent with this, it has been demonstrated that 30-40&#xD;
      percent of patients with advanced breast cancer show an infiltration of foamy macrophages and&#xD;
      fibrosis on lumpectomy/mastectomy samples when chemotherapy is administered for few months&#xD;
      prior to definitive surgery. Further, there is a trend for a more profound change in those&#xD;
      achieving a complete clinical response. Importantly, a complete pathological response in&#xD;
      these advanced breast cancer has been shown to correlate with improved disease free survival&#xD;
      and overall survival in breast cancer patients. A corollary is that if reversibility of early&#xD;
      carcinogenic lesions is reliably demonstrated in our present proposal, it would translate&#xD;
      into chemoprevention of breast cancer.&#xD;
&#xD;
      Specific Aim 3: To compare the pretreatment MRI with post treatment MRI (as a secondary&#xD;
      surrogate endpoint to breast cancer risk reduction). We hypothesize that tumor response can&#xD;
      be measured by contrast washout characteristic in patients with preinvasive and very early&#xD;
      breast cancer treated with aromatase inhibitor. Consistent with this, we have previously&#xD;
      demonstrated that patients with advanced breast cancer show a reduction in vascularity in&#xD;
      response to chemotherapy. Further, there is a trend for a more profound suppression in those&#xD;
      achieving a pathological response on lumpectomy/mastectomy specimen.&#xD;
&#xD;
      Specific Aim 4: To compare the pretreatment markers of angiogenesis with post treatment&#xD;
      markers of angiogenesis (as a secondary surrogate endpoint to breast cancer risk reduction).&#xD;
      We hypothesize that tumor response can be measured by reduction in CD31 (microvessel count),&#xD;
      CD105 (endoglin) and VEGF in response to hormonal therapy. There may be upregulation of&#xD;
      TSP-1, an angiogenesis inhibitor in response to anastrozole. Angiogenic activity has been&#xD;
      reported for ligands of the nuclear hormone receptor superfamily such as estrogens.&#xD;
      Inhibition of the proangiogenic effects of estrogens could underlie the chemopreventive&#xD;
      action of hormone modulators on mammary carcinogenesis. A group of investigators have indeed&#xD;
      coined the word angioprevention as a mechanism of chemoprevention that reverses the&#xD;
      angiogenic switch from preinvasive to invasive cancer. Additionally, it has been demonstrated&#xD;
      that patients with various cancers whose tumor vascularity is targeted with VEGF inhibitor&#xD;
      show higher response than patients who are treated with chemotherapy alone. Our present&#xD;
      proposal capitalizes on the data obtained in advanced breast cancer as to the efficacy of&#xD;
      antiangiogenesis mechanism as an option in treatment and prevention .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2004</start_date>
  <completion_date type="Actual">December 12, 2018</completion_date>
  <primary_completion_date type="Actual">December 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Change in Ki-67 Level</measure>
    <time_frame>Baseline and up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histopathological Response</measure>
    <time_frame>Baseline and up to 4 weeks</time_frame>
    <description>Assessed by changes in Nottingham grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Pretreatment Vascular Density With Post Treatment Vascular Density Using MRI</measure>
    <time_frame>Baseline and 4 weeks after anastrozole</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Pretreatment Markers of Angiogenesis With Post Treatment Marker of Angiogenesis</measure>
    <time_frame>Baseline and up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg. oral every day for 2 - 4 weeks</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>ARIMIDEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have suspicion of DCIS or early invasive breast cancer on mammography.&#xD;
&#xD;
          -  Patients must have histologically confirmed diagnosis of DCIS or early invasive breast&#xD;
             cancer on core biopsy for final registration.&#xD;
&#xD;
          -  Patients must be over 18 years of age&#xD;
&#xD;
          -  &quot;Patients must be postmenopausal as defined by one of the following criteria:&#xD;
&#xD;
               1. Prior bilateral oophorectomy OR&#xD;
&#xD;
               2. &gt; 12 months since LMP with no prior hysterectomy OR&#xD;
&#xD;
               3. a &amp; b not applicable AND age &gt;=50&#xD;
&#xD;
          -  Patients must be positive for either ER or PR or both&#xD;
&#xD;
          -  Patients must be informed of the investigational nature of this study and must sign&#xD;
             and give written informed consent in accordance with institutional and federal&#xD;
             guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have diagnosis of osteoporosis (T-score -2.5 according to the WHO)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://meetinglibrary.asco.org/content/111992-132</url>
    <description>Phase II chemoprevention trial: Anastrozole in DCIS and early invasive hormone-receptor (HR) positive breast cancer in postmenopausal women.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Rita Sanghvi, Mehta</investigator_full_name>
    <investigator_title>Dr. Rita Mehta</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT00256217/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anastrozole</title>
          <description>Anastrozole: 1 mg. oral every day for 2 - 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anastrozole</title>
          <description>Anastrozole: 1 mg. oral every day for 2 - 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" lower_limit="50" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Change in Ki-67 Level</title>
        <time_frame>Baseline and up to 4 weeks</time_frame>
        <population>23 patients had both baseline data and off-treatment data available</population>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg. oral every day for 2 - 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change in Ki-67 Level</title>
          <population>23 patients had both baseline data and off-treatment data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Decreased Ki-67 level</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change in Ki-67</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increased Ki-67 level</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histopathological Response</title>
        <description>Assessed by changes in Nottingham grade</description>
        <time_frame>Baseline and up to 4 weeks</time_frame>
        <population>24 patients had baseline data and post-treatment available.</population>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg. oral every day for 2 - 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Histopathological Response</title>
          <description>Assessed by changes in Nottingham grade</description>
          <population>24 patients had baseline data and post-treatment available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Decreased</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare Pretreatment Vascular Density With Post Treatment Vascular Density Using MRI</title>
        <time_frame>Baseline and 4 weeks after anastrozole</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg. oral every day for 2 - 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare Pretreatment Vascular Density With Post Treatment Vascular Density Using MRI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Decreased</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increased</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare Pretreatment Markers of Angiogenesis With Post Treatment Marker of Angiogenesis</title>
        <time_frame>Baseline and up to 4 weeks</time_frame>
        <population>Data was not collected and analysis of this outcome measure was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg. oral every day for 2 - 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare Pretreatment Markers of Angiogenesis With Post Treatment Marker of Angiogenesis</title>
          <population>Data was not collected and analysis of this outcome measure was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First receipt of first of study drug until 30 days have elapsed following cessation of study drug, a total of up to 8 weeks.</time_frame>
      <desc>There were no reported serious adverse events for this trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anastrozole</title>
          <description>Anastrozole: 1 mg. oral every day for 2 - 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sores in mouth and between fingers</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UC Irvine Health / Chao Family Comprehensive Cancer Center</name_or_title>
      <organization>UC Irvine Health / Chao Family Comprehensive Cancer Center</organization>
      <phone>1-877-UC-STUDY</phone>
      <email>ucstudy@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

